To meet the requirements of regulatory authorities, in particular the Autorité Des Marchés Financiers or "AMF" (French Financial Regulatory Authority), as well as the current European regulations, Biotellytics (hereafter, the "Company") specifies that it is not approved as an Investment Service Provider (Prestataire de Service d'Investissement or "PSI") in France. Nonetheless, in order to address the full scope of the Company's activities, particularly with regards to the Service offered on the website biotechradar.eu, the Company complies with articles 327-1 et seq. of the AMF General Regulation (Book III, Title II, Chapter VII regarding "investment analysts not associated with an Investment Service Provider").
The following texts also apply, among others:
● Regulation (EU) No. 596/2014 of the European Parliament and Council of April 16, 2014, and of the French Monetary and Financial Code
● Delegated Regulation (EU) 2017/565 of the Commission of April 25, 2016 supplementing Directive 2014/65/EU of the European Parliament and Council (also known as the "MiFID 2" Directive) with regards to the organizational requirements and the operating conditions applicable to investment firms and the definition of certain terms for the purposes of this Directive.
In compliance with the provisions of article 327-5 of the AMF General Regulation, the Company has a Code of Ethics defining:
(i) the principles of integrity, independence, competence, and organization that it must comply with
(ii) the methodologies used in the preparation of its analyses.
As foreseen in the Regulation, the Code of Ethics may be consulted at the headquarters or at the business address of the investment analyst. It is also published on the website of the investment analyst if the latter has such a website.